Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.82
ZGNX's Cash to Debt is ranked higher than
68% of the 1158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. ZGNX: 1.82 )
ZGNX' s 10-Year Cash to Debt Range
Min: 0.73   Max: 2.93
Current: 1.82

0.73
2.93
Equity to Asset 0.27
ZGNX's Equity to Asset is ranked higher than
50% of the 965 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. ZGNX: 0.27 )
ZGNX' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.31
Current: 0.27

0.09
0.31
F-Score: 4
Z-Score: -1.17
M-Score: 2.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -49.44
ZGNX's Operating margin (%) is ranked higher than
50% of the 1107 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.08 vs. ZGNX: -49.44 )
ZGNX' s 10-Year Operating margin (%) Range
Min: -299.29   Max: -49.44
Current: -49.44

-299.29
-49.44
Net-margin (%) 21.19
ZGNX's Net-margin (%) is ranked higher than
94% of the 1107 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.46 vs. ZGNX: 21.19 )
ZGNX' s 10-Year Net-margin (%) Range
Min: -313.81   Max: 21.19
Current: 21.19

-313.81
21.19
ROE (%) 21.26
ZGNX's ROE (%) is ranked higher than
91% of the 1135 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.08 vs. ZGNX: 21.26 )
ZGNX' s 10-Year ROE (%) Range
Min: -491.54   Max: 23.3
Current: 21.26

-491.54
23.3
ROA (%) 6.55
ZGNX's ROA (%) is ranked higher than
80% of the 1169 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.54 vs. ZGNX: 6.55 )
ZGNX' s 10-Year ROA (%) Range
Min: -89.81   Max: 5.45
Current: 6.55

-89.81
5.45
ROC (Joel Greenblatt) (%) -172.06
ZGNX's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 1164 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.30 vs. ZGNX: -172.06 )
ZGNX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -509.09   Max: -169.61
Current: -172.06

-509.09
-169.61
Revenue Growth (3Y)(%) -31.70
ZGNX's Revenue Growth (3Y)(%) is ranked lower than
52% of the 948 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. ZGNX: -31.70 )
ZGNX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -31.7
Current: -31.7

» ZGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ZGNX Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce 734,478 sh (-41.99%)
» More
Q2 2014

ZGNX Guru Trades in Q2 2014

Chuck Royce 734,478 sh (unchged)
» More
Q3 2014

ZGNX Guru Trades in Q3 2014

Jim Simons 501,280 sh (New)
Chuck Royce 734,478 sh (unchged)
» More
Q4 2014

ZGNX Guru Trades in Q4 2014

Jim Simons 644,132 sh (+28.50%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 67.10
ZGNX's P/E(ttm) is ranked higher than
68% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 60.40 vs. ZGNX: 67.10 )
ZGNX' s 10-Year P/E(ttm) Range
Min: 50   Max: 81.74
Current: 67.1

50
81.74
PE(NRI) 23.10
ZGNX's PE(NRI) is ranked higher than
88% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 59.00 vs. ZGNX: 23.10 )
ZGNX' s 10-Year PE(NRI) Range
Min: 16.43   Max: 26.86
Current: 23.1

16.43
26.86
P/B 4.40
ZGNX's P/B is ranked higher than
63% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. ZGNX: 4.40 )
ZGNX' s 10-Year P/B Range
Min: 2.5   Max: 202
Current: 4.4

2.5
202
P/S 5.51
ZGNX's P/S is ranked higher than
54% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.25 vs. ZGNX: 5.51 )
ZGNX' s 10-Year P/S Range
Min: 0.33   Max: 15.16
Current: 5.51

0.33
15.16
Current Ratio 1.76
ZGNX's Current Ratio is ranked higher than
64% of the 1028 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.23 vs. ZGNX: 1.76 )
ZGNX' s 10-Year Current Ratio Range
Min: 1.25   Max: 3.24
Current: 1.76

1.25
3.24
Quick Ratio 1.46
ZGNX's Quick Ratio is ranked higher than
68% of the 1028 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. ZGNX: 1.46 )
ZGNX' s 10-Year Quick Ratio Range
Min: 1.25   Max: 2.54
Current: 1.46

1.25
2.54
Days Inventory 169.46
ZGNX's Days Inventory is ranked higher than
65% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 141.66 vs. ZGNX: 169.46 )
ZGNX' s 10-Year Days Inventory Range
Min: 133.82   Max: 419.33
Current: 169.46

133.82
419.33
Days Sales Outstanding 79.94
ZGNX's Days Sales Outstanding is ranked higher than
74% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 89.68 vs. ZGNX: 79.94 )
ZGNX' s 10-Year Days Sales Outstanding Range
Min: 46.47   Max: 79.94
Current: 79.94

46.47
79.94

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.40
ZGNX's Price/Median PS Value is ranked higher than
74% of the 1283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. ZGNX: 1.40 )
ZGNX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 2.63
Current: 1.4

0.12
2.63
Earnings Yield (Greenblatt) -10.10
ZGNX's Earnings Yield (Greenblatt) is ranked lower than
55% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ZGNX: -10.10 )
ZGNX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.1   Max: 2.4
Current: -10.1

-10.1
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:Z08.Germany,
Zogenix Inc was formed as a Delaware Corporation on May 11, 2006. The Company is a pharmaceutical company that develops and commercializes therapies that address specific needs for people living with pain-related conditions and central nervous system disorders who needs treatment alternatives to help them return to normal daily functioning. The Company's first commercial product, Sumavel DosePro Needle-free Delivery System, was launched in January 2010. Sumavel DosePro offers fast-acting, easy-to-use, needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache in a pre-filled, single-use delivery system. Sumavel DosePro is the first drug product approved by the U.S. Food and Drug Administration, or FDA that allows for the needle-free, subcutaneous delivery of medication. Sumavel DosePro may offer a faster-acting and more efficacious treatment alternative to oral and nasal triptans and simple, convenient administration when compared to traditional, needle-based sumatriptan injection. The Company's strategy is to commercialize and develop differentiated central nervous system and pain therapeutics that can address significant unmet medical needs and overcome limitations of existing products. The Company's main product candidate, Zohydro ER, is a 12-hour extended-release formulation of hydrocodone without acetaminophen for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternate treatment options are inadequate. The Company completed Phase 3 development of Zohydro ER in 2011, and submitted an NDA for Zohydro ER to the FDA in May 2012. The FDA approved the NDA for Zohydro ER in October 2013 and the Company launched the product on March 3, 2014. The Company also develops Relday, a proprietary, long-acting injectable formulation of risperidone using Durect Corporation's SABER controlled-release formulation technology through a development and license agreement with Durect Corporation. The Company's competitors include: AstraZeneca plc, Endo Pharmaceuticals Holdings Inc., Johnson & Johnson, Merck & Co., and Pfizer, Inc. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.
» More Articles for ZGNX

Headlines

Articles On GuruFocus.com
Analysts Weigh in on Zogenix in Light of Selling Zohydro Mar 12 2015 
comment on ZGNX Mar 23 2013 
Weekly CFO Buys Highlight: NGL, UNTK, ZGNX, VTSS, RVSB Dec 24 2012 
(ZGNX) CEO Roger Hawley buys 10,000 Shares Dec 06 2010 

More From Other Websites
Zogenix Closes Sale of Zohydro(R) ER Business to Pernix Apr 24 2015
1:02 pm Zogenix confirms its previously announced sale of its Zohydro ER Business to Pernix (Apr 24 2015
Zogenix Closes Sale of Zohydro(R) ER Business to Pernix Apr 24 2015
Coverage initiated on Zogenix by Piper Jaffray Apr 22 2015
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study Mar 26 2015
Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study Mar 26 2015
Pernix to Acquire Zohydro® ER Franchise from Zogenix, Inc. Mar 24 2015
Broadfin Buffs Up on Zogenix, Inc. (ZGNX) and Derma Sciences Inc (DSCI) Mar 19 2015
ZOGENIX, INC. Financials Mar 18 2015
ZOGENIX, INC. Files SEC form 10-K, Annual Report Mar 11 2015
The Gamble That Did Not Pay Off Mar 11 2015
Zogenix (ZGNX) Stock Declines Today Following Sale of Zohydro Mar 11 2015
Zogenix reports 4Q loss Mar 10 2015
Zogenix reports 4Q loss Mar 10 2015
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing... Mar 10 2015
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results Mar 10 2015
ZOGENIX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations... Mar 10 2015
Zogenix Inc Earnings Call scheduled for 4:30 pm ET today Mar 10 2015
Zogenix Announces Agreement of Sale of Zohydro(R) ER Business to Pernix for $100 Million at Closing... Mar 10 2015
Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK